Addition of Quizartinib to Chemotherapy in Newly Diagnosed FLT3-ITD-Positive Acute Myeloid Leukemia
Recommended
Addition of Quizartinib to Chemotherapy in Newly Diagnosed FLT3-ITD-Positive Acute Myeloid Leukemia
Recent research detailed that the phase III QuANTUM-First trial has shown prolonged overall survival with the addition of the FLT3 inhibitor quizartinib to chemotherapy in patients with newly diagnosed FLT3-internal-tandem-duplication-positive acute myeloid leukemia.
Access the full article to read more here.
<!-- BEGIN ADVERTSERVE CODE -->
<div id="mobile_block_ad_1"><script type="text/javascript">
var _avp = _avp || [];
_avp.push({ tagid: 'mobile_block_ad_1', alias: '/', type: 'banner', zid: 1669, pid: 0, onscroll: 0, inview: true, secure: true });
</script></div>
<!-- END ADVERTSERVE CODE -->